Association between anti-TNF-α therapy and all-cause mortality

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 12, 2012, Pages 1311-1320

  Herrinton, Lisa J ^a   Liu, Liyan ^a   Chen, Lang ^b   Harrold, Leslie R ^c   Raebel, Marsha A ^d   Curtis, Jeffrey R ^b   Griffin, Marie R ^e   Solomon, Daniel H ^f   Saag, Kenneth G ^b   Lewis, James D ^g  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d KAISER PERMANENTE   (United States)

^e GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse events; Automated healthcare data; Cohort studies; Crohn's Disease; Drug safety; Drug toxicity; Inflammatory bowel disease; Mortality; Pharmacoepidemiology; Propensity scores; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ALL CAUSE MORTALITY; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; ENTERITIS; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH PROGRAM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870698448     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3354     Document Type: Article

References (24)

1. Grijalva CG, Chen L, Delzell E, et al. Initiation of biologic DMARDs and the risk of hospitalization for infection in patients with autoimmune disease. JAMA 2011; 306: 2331-9.
2. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. Review. Erratum in: JAMA 2006; 295: 2482.
3. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10(2): R30.
4. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8.
5. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5.
6. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82.
7. Burmester GR, Mease PJ, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
8. Lunt M, Watson KD, Dixon WG; British Society for Rheumatology Biologics Register Control Centre Consortium, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. No evidence of association between anti-tumor necrosis factor treatment and mortality in *patients* with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010; 62: 3145-53.
9. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
10. Lewis JD. Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease. Gut 2010; 59: 1586-7.
11. Herrinton LJ, Curtis JR, Chen L, et al. Study Design for a Comprehensive Assessment of Biologic Safety Using Multiple Healthcare Data Systems. Pharmacoepidemiol Drug Saf 2011; 11: 1199-209.
12. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care 2010; 48(6 Suppl): S83-9.
13. Medicaid Analytic eXtract (MAX) General Information. http://www.cms.gov/ MedicaidDataSourcesGenInfo/07_MAXGeneralInformation.asp. Accessed February 15, 2011.
14. Tennessee Government. TennCare. http://www.tn.gov/tenncare/news.html. Accessed February 15, 2011.
15. State of New Jersey. Department of Health and Human Services. Pharmaceutical Assistance to the Aged and Disabled (PAAD). http://www.state.nj.us/health/seniorbenefits/ paad.shtml. Accessed February 15, 2011.
16. Pennsylvania Department of Aging. Prescription Assistance (PACE). http://www.portal.state.pa.us/portal/server.pt/community/prescription_assistance/17942. Accessed February 15, 2011.
17. Kaiser Permanente Division of Research. Member Health Survey. http://www.dor.kaiser.org/external/DORExternal/mhs/index.aspx. Accessed February 15, 2011.
18. Health and Human Services Dept., Centers for Disease Control and Prevention; and Centers for Medicare and Medicaid Services. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 2010.
19. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. Am J Epidemiol 2005; 161: 891-898.
20. Garwood F. Fiducial limits for the Poisson distribution. Biometrika 1936; 28: 437-442.
21. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-8.
22. Centers for Disease Control and Prevention. National Vital Statistics System. Worktable23R. Death Rates by 10-year age groups: United States and each State, 2002. http://www.cdc.gov/nchs/data/dvs/mortfinal2002_work23r.pdf. Accessed July 14, 2011.
23. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7.
24. Lyon SM, Benson NM, Cooke CR, Iwashyna TJ, Ratcliffe SJ, Kahn JM. The Effect of Insurance Status on Mortality and Procedural Utilization in Critically Ill Patients. Am J Respir Crit Care Med 2011; 184: 809-15.